Biosyent (RX) AI Stock Analysis

• Market Cap: C$136.51M
• Dividend Yield: 1.68%
• Average Volume (3M): 2.33K
• Price to Earnings (P/E): 17.5
• Beta (1Y): 0.30
• Revenue Growth: 16.55%
• EPS Growth: 14.70%
• Country: CA
• Employees: 60
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.20
• Shares Outstanding: 11,471,121
• 10 Day Avg. Volume: 1,396
• 30 Day Avg. Volume: 2,330
• PEG Ratio: 1.79
• Price to Book (P/B): 3.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 62.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$13.00
• Price Target Upside: 8.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 80 Outperform
• Price Target: C$13.50 ▲(12.69%Upside)

Biosyent's strong earnings call performance, robust financial health, and stable technical indicators are the key strengths driving the stock score. While the valuation is fair and cash flow management could improve, the company's growth prospects and strategic initiatives support a positive outlook.

Positive Factors

Asset Acquisition

BioSyent announced the acquisition of the global rights to Tibella (Tibolone) for EUR 2.8M (~$4.24M CAD) from Mithra Pharmaceuticals SA and its subsidiary Novalon SA.

Financial Performance

BioSyent reported results that exceeded estimates.

Negative Factors

Asset Quality

No physical assets such as production plants or employees were acquired.

Revenue

The topline came in a bit below estimates.

Biosyent Business Overview & Revenue Model

Company Description

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

How the Company Makes Money

Biosyent Inc. generates revenue primarily through the sale of its pharmaceutical products to healthcare providers, pharmacies, and distributors. The company leverages its expertise in commercializing niche healthcare products across Canada and other international markets. Key revenue streams include prescription sales and over-the-counter product sales. Additionally, Biosyent may engage in strategic partnerships and licensing agreements to expand its product offerings and market reach, contributing to its overall earnings. The company focuses on identifying underutilized or novel products that address unmet medical needs, allowing it to capture market share and drive revenue growth.

Biosyent Financial Statement Overview

Summary

Biosyent demonstrates robust financial health with a strong revenue growth, stable profitability, and efficient cash flow management. The income statement shows a solid performance with high margins and a low debt-to-equity ratio. Although there is a decline in free cash flow growth, the overall financial position is strong, providing a foundation for continued stability and growth.

Income Statement

Biosyent demonstrates strong growth in total revenue, with a 10.89% increase from 2023 to 2024. Gross profit margin remains robust at 79.5%, and net profit margin is healthy at 20.8%. The EBIT and EBITDA margins are solid at 25.0% and 29.8%, respectively, indicating efficient operational management. Overall, the income statement reflects stable profitability and efficient cost management.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.03, suggesting minimal reliance on debt financing, which reduces financial risk. The equity ratio stands at 84.6%, indicating strong capital structure stability. Return on equity is impressive at 20.8%, demonstrating effective utilization of shareholder equity. The balance sheet is well-positioned, with low leverage and strong asset management.

Cash Flow

Biosyent's operating cash flow to net income ratio is favorable at 1.19, reflecting efficient cash generation from operations. However, the free cash flow growth rate shows a decline of 18.14% from 2023 to 2024, indicating potential challenges in maintaining cash reserves. Despite this, the free cash flow to net income ratio is strong at 0.55, showcasing effective cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.28M	35.03M	31.59M	27.93M	28.62M	22.33M
Gross Profit	30.05M	27.86M	25.60M	22.86M	22.64M	17.42M
EBITDA	11.28M	10.43M	9.06M	7.96M	8.92M	5.84M
Net Income	7.82M	7.27M	6.46M	5.46M	6.28M	3.80M
Balance Sheet
Total Assets	42.76M	41.36M	41.53M	40.49M	37.17M	33.57M
Cash, Cash Equivalents and Short-Term Investments	17.40M	15.94M	26.19M	28.70M	28.21M	25.58M
Total Debt	990.22K	1.04M	1.22M	1.40M	1.56M	1.71M
Total Liabilities	6.75M	6.36M	6.77M	7.12M	5.61M	6.78M
Stockholders Equity	36.01M	35.00M	34.76M	33.36M	31.55M	26.80M
Cash Flow
Free Cash Flow	2.17M	3.99M	4.88M	4.43M	4.58M	6.72M
Operating Cash Flow	6.99M	8.66M	5.05M	4.95M	4.67M	6.89M
Investing Cash Flow	4.08M	3.29M	883.85K	-10.79M	-4.84M	3.39M
Financing Cash Flow	-7.19M	-7.83M	-5.78M	-4.37M	-2.08M	-3.37M

Biosyent Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RX, the sentiment is Positive. The current price of 11.98 is above the 20-day moving average (MA) of 11.78, above the 50-day MA of 11.55, and above the 200-day MA of 11.11, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 58.48 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RX.

Biosyent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	80 Outperform	C$136.51M	17.51	22.17%	1.68%	16.55%	14.70%
Sector *	52 Neutral	$7.59B	0.30	-61.86%	2.27%	16.72%	1.10%
THTX		$144.23M	―		―	―	―
MDP	72 Outperform	C$98.71M	22.82	5.27%	―	-1.14%	―
HLS	56 Neutral	C$153.68M	―	-23.05%	―	-3.73%	32.70%
CTX	54 Neutral	C$9.19M	―	-18.52%	―	1.14%	-36.66%
AQS	21 Underperform	C$663.17K	―	43.02%	―	129.21%	26.79%

Biosyent Corporate Events

BioSyent Declares Consistent Second Quarter 2025 Dividend

BioSyent Inc. has announced a quarterly dividend of $0.05 per common share for the second quarter of 2025, payable on June 13, 2025, to shareholders of record as of May 30, 2025. This dividend is consistent with the first quarter’s dividend and is classified as an ‘eligible dividend’ for Canadian tax purposes. The announcement underscores BioSyent’s ongoing commitment to providing shareholder value and reflects its stable financial performance.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent Reports Robust Q1 2025 Financial Performance and Strategic Board Appointment

BioSyent Inc. reported strong financial results for the first quarter of 2025, with total company sales increasing by 42% compared to the first quarter of 2024. The company saw significant growth in its Canadian and international pharmaceutical sales, as well as its legacy business. Notably, the FeraMAX Pd product line continued to lead in the Canadian market for iron health, and the Tibelia product showed substantial growth following the acquisition of global product rights. Despite uncertainties in international trade, BioSyent remains focused on long-term growth and portfolio diversification. Additionally, the company announced the election of Mr. Prakash Gowd to its Board of Directors, succeeding Mr. Larry Andrews.

The most recent analyst rating on (TSE:RX) stock is a Buy with a C$11.75 price target. To see the full list of analyst forecasts on Biosyent stock, see the TSE:RX Stock Forecast page.

BioSyent to Announce Q1 2025 Financial Results on May 15

BioSyent Inc. announced it will release its financial results for the first quarter of 2025 on May 15, 2025, after market hours. The results will be accompanied by a presentation from the company’s President and CEO, René Goehrum, available on their website. This announcement could provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder interests.

BioSyent to Showcase Growth Strategies at 2025 Healthcare Investor Conference

BioSyent Inc. announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, where CEO René Goehrum will present an overview of the company’s business and activities. This event provides an opportunity for BioSyent to engage with investors and potentially strengthen its market position by showcasing its growth-oriented strategies and innovative product offerings.

BioSyent to Participate in Planet MicroCap Showcase 2025

BioSyent Inc. has announced its participation in the Planet MicroCap Showcase: VEGAS 2025 investor conference in Las Vegas, where President and CEO René Goehrum will present and meet with investors. This participation highlights BioSyent’s active engagement with the investment community, potentially enhancing its market visibility and investor relations.